CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via ERK1/2/PPAR&#x03B3; pathway

Xiaoyan Bai; Xiaoyan Hou; Jianwei Tian; Jian Geng; Xiao Li

doi:10.18632/oncotarget.9058

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via ERK1/2/PPARγ pathway

Xiaoyan Bai _, Xiaoyan Hou, Jianwei Tian, Jian Geng and Xiao Li

PDF | HTML | How to cite

Oncotarget. 2016; 7:36510-36528. https://doi.org/10.18632/oncotarget.9058

Metrics: PDF 2722 views | HTML 2978 views | ?

Abstract

Xiaoyan Bai1,*, Xiaoyan Hou1,2,*, Jianwei Tian1,*, Jian Geng3, Xiao Li4

1Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Guangdong Provincial Institute of Nephrology, Guangzhou, Guangdong, PR China

2Division of Nephrology, The First Affiliated Hospital, Inner Mongolia Medical University, Hohhot, Inner Mongolia, PR China

3Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China

4Department of Emergency, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China

*These authors have contributed equally to this work

Correspondence to:

Xiaoyan Bai, e-mail: [email protected], [email protected]

Keywords: CDK5, ERK1/2, PPARγ, tubulointerstitial fibrosis, diabetic nephropathy

Received: September 30, 2015 Accepted: April 16, 2016 Published: April 27, 2016

ABSTRACT

Cyclin-dependent kinase 5 (CDK5) has been documented in podocyte injuries in diabetic nephropathy (DN), however its role in renal tubular epithelial cells has not been elucidated. We report here that CDK5 is detrimental and promotes tubulointerstitial fibrosis (TIF) via the extracellular signal-regulated kinase 1/2 (ERK1/2)/peroxisome proliferator-activated receptor gamma (PPRAγ) pathway in DN. In high glucose cultured NRK52E cells, blocking CDK5 activity inhibited epithelial-to-mesenchymal transition (EMT) and fibrosis via ERK1/2/PPARγ pathway. In diabetic rats, CDK5 inhibitor roscovitine decreased renal fibrosis and improved renal function as demonstrated by a decrease in levels of blood urine nitrogen (BUN), serum creatinine and β2-microglobulin. Further studies revealed that improved renal fibrosis and function in diabetic rats were associated with inactivation of ERK1/2 and PPARγ signaling pathways. In late staged DN patients, the upregulation of CDK5 and p35 activated phosphorylated ERK1/2 and PPARγ, leading to decreased levels of E-cadherin but increased Vimentin and Collagen IV. Accordingly, renal fibrosis and function were worsened as revealed by decreased estimated glomerular filtration rate (eGFR) and increased serum BUN, creatinine, β2-microglobulin, 24-hour proteinuria and urine albumin to creatinine ratio (UACR). These findings demonstrate a novel mechanism that CDK5 increases tubulointerstitial fibrosis by activating the ERK1/2/PPARγ pathway and EMT in DN. CDK5 might have therapeutic potential in diabetic nephropathy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9058

Publication Alerts

Research Papers:

CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via ERK1/2/PPARγ pathway

Abstract